Literature DB >> 29536373

Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?

Jeny Laskar1, Kasturi Bhattacharjee1, Mahuya Sengupta1, Yashmin Choudhury2.   

Abstract

Anti-diabetic drugs are an important group of therapeutics used worldwide. Different anti-diabetic drugs lower blood glucose level by different mechanisms. In recent years, numerous investigations have been performed based on both comparative and cohort studies, in order to establish the relationship between anti-diabetic pharmacotherapy and cancer incidence as well as mortality due to cancer. Some anti-diabetic drugs have been found to exhibit anti-cancer activity while others might increase the risk for cancer. The underlying cause for this disparity is likely to be the varying mechanisms of action of these drugs in controlling blood glucose level. This review discusses the various carcinogenic and/or anti-cancer effects of commonly used anti-diabetic drugs. The information is vital in view of the fact that diabetes mellitus is a commonly occurring disease with a rising incidence rate.

Entities:  

Keywords:  Anti- cancer effect; Anti-diabetic drugs; Cancer risk

Mesh:

Substances:

Year:  2018        PMID: 29536373     DOI: 10.1007/s12253-018-0402-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  120 in total

1.  Inhaled insulin: gone with the wind?

Authors:  C Mathieu; E A M Gale
Journal:  Diabetologia       Date:  2008-01       Impact factor: 10.122

Review 2.  Antidiabetic drugs and risk of cancer.

Authors:  Anna Tokajuk; Edyta Krzyżanowska-Grycel; Adrian Tokajuk; Sławomir Grycel; Anna Sadowska; Halina Car
Journal:  Pharmacol Rep       Date:  2015-05-28       Impact factor: 3.024

3.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Authors:  Isaam Ben Sahra; Claire Regazzetti; Guillaume Robert; Kathiane Laurent; Yannick Le Marchand-Brustel; Patrick Auberger; Jean-François Tanti; Sophie Giorgetti-Peraldi; Frédéric Bost
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

4.  Use of metformin and risk of kidney cancer in patients with type 2 diabetes.

Authors:  Chin-Hsiao Tseng
Journal:  Eur J Cancer       Date:  2015-11-26       Impact factor: 9.162

5.  Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.

Authors:  Chin-Hsiao Tseng
Journal:  Eur J Cancer       Date:  2014-09-05       Impact factor: 9.162

Review 6.  Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Authors:  Joshua J Neumiller
Journal:  J Am Pharm Assoc (2003)       Date:  2009 Sep-Oct

7.  α-glucosidase inhibitors from plants: A natural approach to treat diabetes.

Authors:  Sunil Kumar; Smita Narwal; Vipin Kumar; Om Prakash
Journal:  Pharmacogn Rev       Date:  2011-01

Review 8.  A Review on the Relationship between SGLT2 Inhibitors and Cancer.

Authors:  Hao-Wen Lin; Chin-Hsiao Tseng
Journal:  Int J Endocrinol       Date:  2014-08-31       Impact factor: 3.257

Review 9.  Diabetes mellitus carries a risk of esophageal cancer: A meta-analysis.

Authors:  Bo Xu; Xiufang Zhou; Xiaohong Li; Chaoyang Liu; Caizhe Yang
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

10.  Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.

Authors:  Chin-Hsiao Tseng
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more
  3 in total

Review 1.  Hyperglycemia-Induced Aberrant Cell Proliferation; A Metabolic Challenge Mediated by Protein O-GlcNAc Modification.

Authors:  Tamás Nagy; Viktória Fisi; Dorottya Frank; Emese Kátai; Zsófia Nagy; Attila Miseta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

Review 2.  Targeting Glucose Metabolism to Enhance Immunotherapy: Emerging Evidence on Intermittent Fasting and Calorie Restriction Mimetics.

Authors:  William J Turbitt; Wendy Demark-Wahnefried; Courtney M Peterson; Lyse A Norian
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 3.  Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence.

Authors:  Aurora Mirabile; Licia Rivoltini; Elena Daveri; Claudio Vernieri; Roberto Mele; Luca Porcu; Chiara Lazzari; Alessandra Bulotta; Maria Grazia Viganò; Stefano Cascinu; Vanesa Gregorc
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.